Change in the hepatic profile of hepatitis C virus genotype 4–infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE‐II study

In AGATE‐II, treatment with ombitasvir coformulated with paritaprevir/ritonavir plus ribavirin (RBV) in Egyptians infected with hepatitis C virus genotype 4 resulted in high rates of sustained virologic response at post‐treatment week 12. This subanalysis examined the effects of treatment in AGATE‐I...

Descripción completa

Detalles Bibliográficos
Autores principales: Waked, Imam, Esmat, Gamal, Fouad, Rabab, Allam, Naglaa, Hassany, Mohamed, Mohey, Mohammad, Shiha, Gamal, Soliman, Reham, Qaqish, Roula B., Hall, Coleen, Alami, Negar N., Kopecky‐Bromberg, Sarah, Mobashery, Niloufar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767547/
https://www.ncbi.nlm.nih.gov/pubmed/29900553
http://dx.doi.org/10.1002/jmv.25243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767547/
https://www.ncbi.nlm.nih.gov/pubmed/29900553
http://dx.doi.org/10.1002/jmv.25243

Ejemplares similares